Optimer Pharmaceuticals, Inc. (OPTR)

[surf1944]

7:02AM Optimer Pharma publishes Phase 3 results confirming superior rate of sustained clinical response of Dificid tablets compared to oral Vancomycin in adult patients with Clostridium difficile infection (OPTR) 13.51 : Co announced today The Lancet Infectious Diseases has published results from the European and North American Phase 3 trial evaluating the safety and efficacy of DIFICID (fidaxomicin) tablets in the treatment of adult patients with Clostridium difficile infection (CDI). The Phase 3 non-inferiority trial showed that DIFICID had similar clinical cure rates as oral vancomycin in the initial treatment of the disease. In addition, secondary endpoint analyses showed that DIFICID provided superior rates of sustained clinical response through 25 days after the end of treatment and had significantly lower recurrence rates within four weeks of treatment.